Designation of Icatibant (Firazyr) as an Orphan Drug - Shire Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation of therapeutic goods to ensure their safety, quality, and efficacy. This legislation was introduced to fill the gap in the regulation of medical products, ensuring that they meet necessary standards before being made available to the public. One of the specific objectives of the Act, as evidenced by the designation of Icatibant (FIRAZYR) as an orphan drug for the treatment of angiotensin-converting-enzyme inhibitor (ACE-1) induced angioedema, is to facilitate the development and availability of treatments for rare diseases. The designation was made by Dr. Anthony Gill, the Delegate of the Secretary, on 10 October 2013, under the authority granted by subregulation 16J(2) of the Therapeutic Goods Regulations 1990, aiming to support the development of therapeutic options for conditions that affect a small number of people, thereby addressing a critical need in healthcare.

Scope and Application

The Therapeutic Goods Act 1989 designates certain therapeutic goods based on specific criteria, including the designation of Icatibant (FIRAZYR) as an orphan drug. This designation applies to the pharmaceutical product Icatibant, manufactured by Shire Australia Pty Ltd, which is designated for the treatment of angiotensin-converting-enzyme inhibitor (ACE-1) induced angioedema. The Act and its regulations, administered by the Therapeutic Goods Administration, have a broad jurisdictional reach across the Commonwealth of Australia, governing the importation, supply, and registration of therapeutic goods. This particular designation under the Therapeutic Goods Regulations 1990 targets orphan drugs, which are medications developed to treat rare medical conditions. The geographic scope of this legislation is national, impacting all entities involved in the supply and registration of therapeutic goods within Australia. No specific exclusions or thresholds are noted in this particular designation; however, the broader regulatory framework might include various exclusions, exemptions, or thresholds applicable to different therapeutic goods and their classifications. The application and interpretation of the Act can be extended or restricted through subordinate instruments issued by the Therapeutic Goods Administration.

Key Provisions

The Therapeutic Goods Act 1989, through its Therapeutic Goods Regulations 1990, includes specific provisions that allow for the designation of certain drugs as orphan drugs. Section 16J of these Regulations provides the authority for such designation, which is intended to facilitate the development of drugs for small patient populations with serious or life-threatening conditions for which there are no adequate treatments. In this particular instance, Section 16J(2) of the Regulations has been utilised by Dr Anthony Gill, a Delegate of the Secretary, to designate Icatibant (FIRAZYR) as an orphan drug. This designation applies to Icatibant's use in treating angiotensin-converting-enzyme inhibitor (ACE-1) induced angioedema, with the drug being administered as a solution for injection (Section 16J(2)). The sponsor of Icatibant (FIRAZYR) is Shire Australia Pty Ltd, indicating their role in the development and potential marketing of the drug for this specified indication. The designation of Icatibant (FIRAZYR) as an orphan drug under the Therapeutic Goods Regulations 1990 comes with specific obligations and requirements for the parties involved. The sponsor, Shire Australia Pty Ltd, must ensure that the drug is developed and marketed in a manner that adheres to the therapeutic needs of the targeted patient population. This includes providing sufficient evidence of the drug’s efficacy and safety for the designated condition. Additionally, the sponsor must comply with any other regulatory requirements outlined in the Therapeutic Goods Act and Regulations, which may include clinical trial approvals, manufacturing standards, and labelling requirements tailored to orphan drugs. The Therapeutic Goods Administration (TGA) plays a crucial role in overseeing these obligations, ensuring that the orphan drug designation is upheld and that the drug meets the necessary standards before it can be made available to patients. Breaching the provisions of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in significant legal consequences. For instance, failing to comply with the requirements for orphan drug designation or misrepresenting the drug’s therapeutic value could lead to enforcement actions by the TGA. Such actions may include the issuance of infringement notices, which can incur fines up to a certain amount as stipulated by the Act. More serious breaches, such as the distribution of unsafe or ineffective drugs, can result in criminal charges. Under Section 32DA of the Act, individuals or companies found guilty of serious offences can face substantial fines and, in some cases, imprisonment. The specific penalties depend on the nature and severity of the offence, with maximum penalties outlined in relevant sections of the Act and Regulations. Ensuring compliance with these legal requirements is essential for avoiding these potential penalties and for maintaining the integrity of the therapeutic goods regulatory framework in Australia.